LL-37 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
LL-37 (Human cathelicidin antimicrobial peptide LL-37) is a Antimicrobial peptide, host defense peptide researched for broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement. For beginners, start at the lower end of the dosage range (100-500 mcg (topical/local application)) and administer topical or local application as needed via topical wound application, local injection, intranasal.
What Is LL-37?
LL-37 (Human cathelicidin antimicrobial peptide LL-37) is a Antimicrobial peptide, host defense peptide. Endogenous human antimicrobial peptide; the only human member of the cathelicidin family; produced by neutrophils, macrophages, and epithelial cells.
It is researched for its potential effects on broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement. The human body's own antibiotic peptide with multiple killing mechanisms that prevent bacterial resistance development — unlike conventional antibiotics, bacteria cannot easily evolve resistance to membrane disruption.
For beginners: This guide assumes no prior peptide experience. We'll cover everything from what LL-37 is to how to reconstitute, inject, and structure your first cycle.
How Does LL-37 Work?
Kills pathogens through multiple mechanisms: converts from random coil to α-helix structure, burrows into bacterial membranes causing permeabilization (carpet model), generates oxidative stress in bacterial cells, and disrupts biofilms and viral envelopes. Also immunomodulatory — activates chemokine receptors and enhances inflammatory response. Effective against 38+ bacteria, 16 fungi, and 16 viruses.
Understanding the mechanism helps set realistic expectations about what LL-37 can and cannot do.
How Do You Get Started With LL-37?
Step 1 — Source: Purchase LL-37 from a vendor with third-party Certificate of Analysis (COA) testing. This confirms purity (aim for 98%+) and rules out contamination.
Step 2 — Supplies: You'll need bacteriostatic water, insulin syringes (1mL/100-unit), alcohol swabs, and a clean workspace.
Step 3 — Reconstitute: Add BAC water to the LL-37 vial — use our peptide calculator for exact amounts. Let the water run down the side of the vial; never spray directly on the powder. Swirl gently.
Step 4 — Dose: Draw 100-500 mcg (topical/local application) using the calculator's syringe unit conversion.
Step 5 — Inject: Clean the injection site with alcohol. Pinch a fold of abdominal fat and insert the needle at 45° for subcutaneous injection. Push the plunger slowly and hold for 5 seconds.
Calculate Your LL-37 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for LL-37.
Open Calculator →What Should Your First LL-37 Cycle Look Like?
Dosage: Start at the lower end of 100-500 mcg (topical/local application). This lets you assess tolerance before committing to a full cycle.
Frequency: topical or local application as needed via topical wound application, local injection, intranasal.
Duration: acute use as needed. Don't cut cycles short — many Antimicrobial peptide, host defense peptide effects take weeks to fully manifest.
Off-cycle: Plan a 4-week break before starting another cycle.
What Side Effects Should Beginners Watch For?
Dose-dependent cytotoxicity to human cells above 75 mcg/mL. Hemolytic effects at high concentrations. Proteolytic degradation limits bioavailability. Potential immune overstimulation.
As a beginner, track everything — dose, time, injection site, and any effects (positive or negative). This data helps optimize future cycles.
What Are Common Beginner Mistakes?
Not using BAC water: Sterile water lacks the preservative that prevents bacterial growth. Always use bacteriostatic water.
Inconsistent dosing: Skipping doses or varying timing significantly reduces outcomes. Set a daily alarm.
Poor storage: Reconstituted LL-37 must stay refrigerated at 2-8°C. Leaving it at room temperature degrades the compound rapidly.
Buying cheap: Low-cost peptides without COA testing may be underdosed, contaminated, or mislabeled. Quality matters more than price.
Bottom Line for LL-37 Beginners
Start at the lower end of 100-500 mcg (topical/local application), dose topical or local application as needed, cycle for acute use as needed, and track everything. Source from COA-tested vendors and follow proper reconstitution protocol.
Read our complete peptide beginner's guide for general peptide education beyond LL-37.
Complete Guide
LL-37 : Benefits, Dosage, Side Effects & Research
Related Reading
- LL-37 Dosage Guide
- LL-37 Benefits
- LL-37 Side Effects
- LL-37 Stacking Guide
- LL-37 Cycle Guide
- LL-37 Research
Research-Grade Sourcing
If you're going to research LL-37, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is LL-37?
LL-37 (Human cathelicidin antimicrobial peptide LL-37) is a Antimicrobial peptide, host defense peptide. Endogenous human antimicrobial peptide; the only human member of the cathelicidin family; produced by neutrophils, macrophages, and epithelial cells. It is researched for broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement.
What is the recommended LL-37 dosage?
Common dosages: 100-500 mcg (topical/local application) administered topical or local application as needed via topical wound application, local injection, intranasal. Cycle length: acute use as needed. Half-life: rapidly degraded by proteases; major clinical limitation. Use our peptide calculator for exact reconstitution math.
What are the side effects of LL-37?
Dose-dependent cytotoxicity to human cells above 75 mcg/mL. Hemolytic effects at high concentrations. Proteolytic degradation limits bioavailability. Potential immune overstimulation.
Is LL-37 safe?
LL-37 has shown a preliminary safety profile in research. Not FDA-approved as therapeutic. Research compound. Derivatives in late-stage clinical trials. All research should follow appropriate safety protocols.